The Pfizer Clinical Research Unit is conducting a clinical trial of a study drug for atopic dermatitis (eczema; AD). This study will look at the effects of the study drug when single oral doses are given to healthy volunteers without food.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin conditions. It causes a rash and itching and can negatively affect patients’ emotional well-being. There is no cure for AD and, while available treatments may provide symptom relief, the community needs new long-term treatment options.
Learn how you can support patients as a healthy volunteer below.
Who may participate
Healthy clinical trial participants are a critical part of early drug development and build the foundation for later phases of research.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
**females must be unable to bear children
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-65 years
Sex
All sexes
Referral bonus
Up to $250
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 8 consecutive overnights. On the morning after admission, you will receive a single oral dose of the study drug, or a dose of placebo (which has no active ingredient). All of the doses will be provided as tablets which you will swallow and will be provided after an overnight fast. About 2 weeks after the last dose, you will return for a follow-up visit (this does not involve staying overnight). A final follow-up call will be completed about 4 weeks after your dose.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
Required overnight stays
8
Long-term follow up
1 visit + 1 phone call
How long is this study?
Up to about 37 days
Compensation
Up to $4,200 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent document (ICD).